Going from Sneezes to Smiles with Wyndly's Innovative Allergy Care
- Wyndly uses sublingual immunotherapy to offer a convenient alternative to traditional allergy treatments.
- Its approach uses tiny doses of allergens to help build the body's tolerance over time.
- The company secured $2 million in funding to expand access to allergy treatment.
I can easily imagine a world where I’m constantly sneezing, my eyes are red and itchy, and I carry tissues everywhere.
This is my reality, thanks to a severe dust allergy and the lack of a long-term solution for relief. Millions of others experience the same struggle.
Allergies are more than a nuisance. They can significantly lower a person's quality of life.
Wyndly's approach to allergy care
Before Wyndly, allergy sufferers had options such as antihistamines and allergy shots. Antihistamines provided temporary relief without addressing the root cause, while allergy shots were time-consuming, painful, and required frequent visits to a doctor's office.
Wyndly takes a different approach through its allergy-care service.
Its treatment uses sublingual immunotherapy, which involves placing tiny doses of allergens under the tongue to gradually build the body's tolerance over time.
How sublingual immunotherapy works
Unlike conventional treatments, sublingual immunotherapy targets the root cause of allergies by retraining the immune system.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
The treatment helps the body recognise that allergens such as pollen and dust mites are harmless. Over time, the immune system stops overreacting, and allergy symptoms can diminish or disappear.
Wyndly currently offers sublingual immunotherapy as part of its allergy-care service.
The effects of untreated allergies
Untreated allergies can escalate into more serious health issues. Chronic sinus infections, sleep disorders, and asthma can develop if allergies are not properly managed.
Wyndly's mission is to improve allergy care and prevent potentially dangerous complications.
Wyndly's founders and funding
Wyndly was founded by Dr. Manan Shah and Aakash Shah. Wyndly secured $2 million in funding to expand its mission of providing accessible allergy treatment to more people.
Life after allergy treatment
People using Wyndly were living symptom-free lives, enjoying the outdoors, sleeping soundly, and relying less on tissues and over-the-counter medication.
Wyndly's allergy-care model combines sublingual immunotherapy with an effort to make treatment more accessible. Its founders, Dr. Manan Shah and Aakash Shah, secured $2 million in funding to continue that mission.
More in Health care
